Pharmaceuticals 2014, 7(2), 113-135; doi:10.3390/ph7020113
Review

From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy

1 Department of Medicinal Chemistry, Intra-cellular Therapies Inc. 3960 Broadway, New York, NY 10032, USA 2 Department of Organic Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel 3 Abital Pharma Pipeline Ltd., Tel Aviv 6789141, Israel
* Author to whom correspondence should be addressed.
Received: 16 December 2013; in revised form: 13 January 2014 / Accepted: 17 January 2014 / Published: 23 January 2014
(This article belongs to the Special Issue CNS-Drugs and Therapy)
PDF Full-text Download PDF Full-Text [389 KB, uploaded 23 January 2014 14:14 CET]
Abstract: Brain network dysfunction in Alzheimer’s disease (AD) involves many proteins (enzymes), processes and pathways, which overlap and influence one another in AD pathogenesis. This complexity challenges the dominant paradigm in drug discovery or a single-target drug for a single mechanism. Although this paradigm has achieved considerable success in some particular diseases, it has failed to provide effective approaches to AD therapy. Network medicines may offer alternative hope for effective treatment of AD and other complex diseases. In contrast to the single-target drug approach, network medicines employ a holistic approach to restore network dysfunction by simultaneously targeting key components in disease networks. In this paper, we explore several drugs either in the clinic or under development for AD therapy in term of their design strategies, diverse mechanisms of action and disease-modifying potential. These drugs act as multi-target ligands and may serve as leads for further development as network medicines.
Keywords: memantine; nitromemantine; NMDA antagonist; M30; M30D; AChE-MAO-A/B inhibitor; chelator; Ginkgo biloba

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Zheng, H.; Fridkin, M.; Youdim, M. From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy. Pharmaceuticals 2014, 7, 113-135.

AMA Style

Zheng H, Fridkin M, Youdim M. From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy. Pharmaceuticals. 2014; 7(2):113-135.

Chicago/Turabian Style

Zheng, Hailin; Fridkin, Mati; Youdim, Moussa. 2014. "From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy." Pharmaceuticals 7, no. 2: 113-135.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert